CTOR Stock Analysis: Buy, Sell, or Hold?
CTOR - Citius Oncology, Inc. Common Stock
$0.62
-0.04 (-6.06%)
▼
5d:
-7.42%
30d:
-30.25%
90d:
+14.6%
HOLD
MODERATE Confidence
Analysis Updated: Jun 26, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CTOR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CTOR trades at premium valuation expecting 25.6% growth. Hold existing positions but don't chase. Wait for better entry.
📊 HOLD: CTOR trades at premium valuation expecting 25.6% growth. Hold existing positions but don't chase. Wait for better entry.
In-depth Analysis How we analyze
Valuation Analysis: CTOR is currently trading at $0.62, which is considered oversold relative to its 30-day fair value range of $0.67 to $0.82. From a valuation perspective, the stock is trading at a premium (Forward PE: 6.2) compared to its historical average (3.1). At these levels, the market is pricing in 25.6% annual earnings growth. This is a high bar to clear, indicating the stock may be priced for perfection.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+545.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CTOR is in a downtrend. The price is currently testing key support at $0.66. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: CTOR has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $4.00 (+545.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.67 -
$0.82
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 545.2% below Wall St target ($4.00)
- BEARISH: Market expects 25.6% growth - appears too optimistic based on history
- CAUTION: 5-day price weakness (-7.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.67 -
$0.82
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.66
Resistance Level
$0.85
Current Trend
Downtrend
Technical data as of
Jun 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
6.20
Wall Street Target
$4.00
(+545.2%)
Valuation Premium vs History
+25.6% premium
PE vs Historical
6.2 vs 3.1
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+25.6%
(market-implied from PE analysis)
1-Year Target
$0.78
(+26%)
2-Year Target
$0.98
(+58%)
3-Year Target
$1.23
(+98%)
3-Yr Target (if PE normalizes)
(PE: 6→3)
PE COMPRESSION
$0.61
(-1%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 28, 2026 4:27 PM ET
Data refreshes hourly during market hours. Next update: 5:27 PM
Data refreshes hourly during market hours. Next update: 5:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTOR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 60 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 54 HOLD |